Navigation Links
Hillenbrand Industries, Inc. Announces Expiration and Final Results of its Previously Announced 'Any and All' Cash Tender Offer for its 4.50 Percent Senior Notes Due 2009
Date:3/31/2008

BATESVILLE, Ind., March 31 /PRNewswire-FirstCall/ -- Hillenbrand Industries, Inc. (NYSE: HB) (the "Company") announced the expiration and final results of its previously announced cash tender offer to purchase any and all of its outstanding 4.50 percent Senior Notes due 2009 (CUSIP No. 431573AD6). The tender offer was made pursuant to an Offer to Purchase dated February 29, 2008 (the "Offer to Purchase") and the related Letter of Transmittal, which set forth a more comprehensive description of the terms of the tender offer.

The tender offer expired at 8 a.m., New York City time, on March 31, 2008. $224,265,000 in aggregate principal amount of notes, representing approximately 89.7 percent of the outstanding notes, were validly tendered (and not validly withdrawn) in the tender offer.

The Company has waived all of the conditions to the tender offer and has accepted for purchase all of the notes validly tendered (and not validly withdrawn) in the tender offer. The Company has paid to the Depository Trust Company the total consideration payable to holders in the tender offer and has irrevocably instructed Global Bondholder Services Corporation, the depositary for the tender offer, to pay the full tender offer consideration or late tender offer consideration, as applicable, plus accrued interest, to the tendering holders on the settlement date, which is tomorrow, April 1, 2008.

Citi and Goldman, Sachs & Co. served as the dealer managers for the tender offer and Global Bondholder Services Corporation served as the depositary and information agent for the tender offer.

ABOUT HILLENBRAND INDUSTRIES, INC.

Hillenbrand Industries is organized into two operating companies serving the health care and funeral services
'/>"/>

SOURCE Hillenbrand Industries, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Hillenbrand Industries Announces Fourth Quarter 2007 Dividend
2. Hillenbrand Industries Announces Second Quarter 2008 Dividend
3. Hillenbrand Announces Mailing of Proxy Regarding Changing of Company Name in Conjunction with Planned Separation
4. Hillenbrand Industries, Inc. Announces Any and All Cash Tender Offer for Its 4.50 percent Senior Notes Due 2009
5. Hillenbrand Releases Investor Roadshow Materials and Updated Financial Guidance Related to Separation Of Hill-Rom and Batesville Casket
6. Hillenbrand Industries, Inc. Announces Early Tender Results of its Pending Any and All Cash Tender Offer for its 4.50 Percent Senior Notes Due 2009
7. Hillenbrand Industries Announces Formal Board Approval of Separation by Means of Share Distribution and Details for Completion
8. Batesville Holdings Announces New Board of Directors in Preparation for March 31 Spin-Off from Hillenbrand Industries
9. Hillenbrand Industries, Inc. Announces Pricing of Its Pending Any and All Cash Tender Offer for Its 4.50 percent Senior Notes Due 2009
10. Herley Industries, Inc. Receives a $5 Million Award from EDO for Electronic Components for IEDs
11. Statement by Bonnie J. Campbell, Former Attorney General of Iowa and Spokesperson for Atlantic Richfield Co., Millennium Holdings, LLC, NL Industries, Inc., and The Sherwin-Williams Company on the Jury Verdict Reached Today in the Thomas (Milwaukee) Case
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine Technology:Efficacy and Safety Profile of Basilea's Alitretinoin for Severe,Refractory Chronic Hand Eczema Confirmed by Data Shown at European,Dermatology Congress 2Efficacy and Safety Profile of Basilea's Alitretinoin for Severe,Refractory Chronic Hand Eczema Confirmed by Data Shown at European,Dermatology Congress 3Efficacy and Safety Profile of Basilea's Alitretinoin for Severe,Refractory Chronic Hand Eczema Confirmed by Data Shown at European,Dermatology Congress 4Efficacy and Safety Profile of Basilea's Alitretinoin for Severe,Refractory Chronic Hand Eczema Confirmed by Data Shown at European,Dermatology Congress 5Oncophage Cancer Vaccine Significantly Prolongs Recurrence-Free,Survival by 45 Percent in Patients With Intermediate-Risk Kidney,Cancer 2Oncophage Cancer Vaccine Significantly Prolongs Recurrence-Free,Survival by 45 Percent in Patients With Intermediate-Risk Kidney,Cancer 3Oncophage Cancer Vaccine Significantly Prolongs Recurrence-Free,Survival by 45 Percent in Patients With Intermediate-Risk Kidney,Cancer 4Oncophage Cancer Vaccine Significantly Prolongs Recurrence-Free,Survival by 45 Percent in Patients With Intermediate-Risk Kidney,Cancer 5Oncophage Cancer Vaccine Significantly Prolongs Recurrence-Free,Survival by 45 Percent in Patients With Intermediate-Risk Kidney,Cancer 6